Ultragenyx Pharmaceutical (RARE) Retained Earnings (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Retained Earnings data on file, last reported at -$4.5 billion in Q4 2025.

• On a quarterly basis, Retained Earnings fell 207.57% year-over-year to -$4.5 billion in Q4 2025; TTM through Dec 2025 was -$4.5 billion, a 207.57% decrease from a year earlier, with the FY2025 full-year figure at -$4.5 billion, down 207.57% from the prior year.
• Retained Earnings for Q4 2025 stood at -$4.5 billion, down from $4.4 billion in the prior quarter.
• Over the last five years, Retained Earnings for RARE reached as high as $4.4 billion in Q3 2025 and fell as low as -$4.5 billion in Q4 2025.
• Historically, Retained Earnings has averaged $597.4 million across 5 years, with a median of -$718000.0 in 2024.
• Across the five-year window, Retained Earnings sank 44834.3% in 2023 and jumped 399582.47% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$2.1 billion in 2021, then plunged by 34.12% to -$2.8 billion in 2022, then jumped by 231.69% to $3.7 billion in 2023, then gained by 15.04% to $4.2 billion in 2024, then tumbled by 207.57% to -$4.5 billion in 2025.
• Per Business Quant data, the three most recent Retained Earnings figures were -$4.5 billion in Q4 2025, $4.4 billion in Q3 2025, and $4.4 billion in Q2 2025.